Troxatyl™ (troxacitabine) has activity in blastic phase chronic myeloid leukemia (CMLBP)

F. J. Giles, J. E. Cortes, C. Bivins M, Andreeff, M. Talpaz, J. Jolivet, H. M. Kantarjian

Research output: Contribution to journalArticle

Abstract

Troxatyl™ is the first dioxolane nucleoside with potent in vitro and in vivo antitumor activity. This cytosine analog is a DNA polymerase inhibitor and complete DNA chain terminator. It undergoes cellular uptake with prolonged retention of the phosphorylated metabolites. Troxatyl™ is not a substrate for cytidine deaminase and is the only L-isomer nucleoside analog with anti-tumor activity. In a Phase I study of Troxatyl™ in patients (pts) with primary refractory or relapsed acute leukemia, mucositis and hand-foot syndrome were the dose limiting toxicities. (Giles el al Abstract 4231 ASH 1999). The recommended single agent dose was defined as 8 mg/m2/day daily for 5 days. Preliminary results are presented for 13 pts ( 10 female and 3 male, median age:52 years; range:23-80), with CMLBP treated at this dose as part of an ongoing Phase II study. Prior therapy for CML chronic phase included hydroxyurea alone (1 pt), alpha interferon-based therapy (7 pts), homoharringtonine (HHT) ( 1 pt), allogeneic Stem Cell Transplantation (SCT) ( 1 pt). Eleven pts had received and failed one or more prior therapy for CMLBP including topotecanbased therapy (5 pts), allogeneic SCT (3 pts), 6-thioguanine (1 pt), HHT (2 pts), mitoxantrone/ ara-C (1 pt), STI (5 pts), donor lymphocyte infusions (1 pt), 2-CDA/cyclophosphamide/ VP16U pt),hCVXD(l pt),clofarabine/decitabine(l pt),liposomalDaunorubicin/ara-C(l pt), CVAD (1 pt). Toxicities included: Grade 2 skin rash - 5 pts; hand-foot syndrome: Grade 2-4 pts, Grade 3-3 pts; Grade 2 mucositis - 1 pt; Grade 4 mucositis - 2 pts. Three patients were converted to 2nd chronic phase with a median duration of 10 months (range 9-16). Two pts had early deaths from progressive disease and two others are too early to assess. Four patients have received two or more courses of therapy. Troxatyl(tm) has activity in heavily pretreated patients with CMLBP and merits further study in first line as a single agent and in combination.

Original languageEnglish (US)
Pages (from-to)254b
JournalBlood
Volume96
Issue number11 PART II
StatePublished - Dec 1 2000
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Cytarabine
decitabine
Stem cells
Nucleosides
Toxicity
Cytidine Deaminase
Nucleic Acid Synthesis Inhibitors
Thioguanine
Emitter coupled logic circuits
Mitoxantrone
Hydroxyurea
Lymphocytes
Cytosine
Metabolites
Interferon-alpha
Isomers
Refractory materials
Cyclophosphamide
Mucositis

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Giles, F. J., Cortes, J. E., Bivins M, C., Andreeff, Talpaz, M., Jolivet, J., & Kantarjian, H. M. (2000). Troxatyl™ (troxacitabine) has activity in blastic phase chronic myeloid leukemia (CMLBP). Blood, 96(11 PART II), 254b.

Troxatyl™ (troxacitabine) has activity in blastic phase chronic myeloid leukemia (CMLBP). / Giles, F. J.; Cortes, J. E.; Bivins M, C.; Andreeff; Talpaz, M.; Jolivet, J.; Kantarjian, H. M.

In: Blood, Vol. 96, No. 11 PART II, 01.12.2000, p. 254b.

Research output: Contribution to journalArticle

Giles, FJ, Cortes, JE, Bivins M, C, Andreeff, Talpaz, M, Jolivet, J & Kantarjian, HM 2000, 'Troxatyl™ (troxacitabine) has activity in blastic phase chronic myeloid leukemia (CMLBP)', Blood, vol. 96, no. 11 PART II, pp. 254b.
Giles FJ, Cortes JE, Bivins M C, Andreeff, Talpaz M, Jolivet J et al. Troxatyl™ (troxacitabine) has activity in blastic phase chronic myeloid leukemia (CMLBP). Blood. 2000 Dec 1;96(11 PART II):254b.
Giles, F. J. ; Cortes, J. E. ; Bivins M, C. ; Andreeff ; Talpaz, M. ; Jolivet, J. ; Kantarjian, H. M. / Troxatyl™ (troxacitabine) has activity in blastic phase chronic myeloid leukemia (CMLBP). In: Blood. 2000 ; Vol. 96, No. 11 PART II. pp. 254b.
@article{dc8fbed4fa83403d840258d6beb48fba,
title = "Troxatyl™ (troxacitabine) has activity in blastic phase chronic myeloid leukemia (CMLBP)",
abstract = "Troxatyl™ is the first dioxolane nucleoside with potent in vitro and in vivo antitumor activity. This cytosine analog is a DNA polymerase inhibitor and complete DNA chain terminator. It undergoes cellular uptake with prolonged retention of the phosphorylated metabolites. Troxatyl™ is not a substrate for cytidine deaminase and is the only L-isomer nucleoside analog with anti-tumor activity. In a Phase I study of Troxatyl™ in patients (pts) with primary refractory or relapsed acute leukemia, mucositis and hand-foot syndrome were the dose limiting toxicities. (Giles el al Abstract 4231 ASH 1999). The recommended single agent dose was defined as 8 mg/m2/day daily for 5 days. Preliminary results are presented for 13 pts ( 10 female and 3 male, median age:52 years; range:23-80), with CMLBP treated at this dose as part of an ongoing Phase II study. Prior therapy for CML chronic phase included hydroxyurea alone (1 pt), alpha interferon-based therapy (7 pts), homoharringtonine (HHT) ( 1 pt), allogeneic Stem Cell Transplantation (SCT) ( 1 pt). Eleven pts had received and failed one or more prior therapy for CMLBP including topotecanbased therapy (5 pts), allogeneic SCT (3 pts), 6-thioguanine (1 pt), HHT (2 pts), mitoxantrone/ ara-C (1 pt), STI (5 pts), donor lymphocyte infusions (1 pt), 2-CDA/cyclophosphamide/ VP16U pt),hCVXD(l pt),clofarabine/decitabine(l pt),liposomalDaunorubicin/ara-C(l pt), CVAD (1 pt). Toxicities included: Grade 2 skin rash - 5 pts; hand-foot syndrome: Grade 2-4 pts, Grade 3-3 pts; Grade 2 mucositis - 1 pt; Grade 4 mucositis - 2 pts. Three patients were converted to 2nd chronic phase with a median duration of 10 months (range 9-16). Two pts had early deaths from progressive disease and two others are too early to assess. Four patients have received two or more courses of therapy. Troxatyl(tm) has activity in heavily pretreated patients with CMLBP and merits further study in first line as a single agent and in combination.",
author = "Giles, {F. J.} and Cortes, {J. E.} and {Bivins M}, C. and Andreeff and M. Talpaz and J. Jolivet and Kantarjian, {H. M.}",
year = "2000",
month = "12",
day = "1",
language = "English (US)",
volume = "96",
pages = "254b",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART II",

}

TY - JOUR

T1 - Troxatyl™ (troxacitabine) has activity in blastic phase chronic myeloid leukemia (CMLBP)

AU - Giles, F. J.

AU - Cortes, J. E.

AU - Bivins M, C.

AU - Andreeff,

AU - Talpaz, M.

AU - Jolivet, J.

AU - Kantarjian, H. M.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Troxatyl™ is the first dioxolane nucleoside with potent in vitro and in vivo antitumor activity. This cytosine analog is a DNA polymerase inhibitor and complete DNA chain terminator. It undergoes cellular uptake with prolonged retention of the phosphorylated metabolites. Troxatyl™ is not a substrate for cytidine deaminase and is the only L-isomer nucleoside analog with anti-tumor activity. In a Phase I study of Troxatyl™ in patients (pts) with primary refractory or relapsed acute leukemia, mucositis and hand-foot syndrome were the dose limiting toxicities. (Giles el al Abstract 4231 ASH 1999). The recommended single agent dose was defined as 8 mg/m2/day daily for 5 days. Preliminary results are presented for 13 pts ( 10 female and 3 male, median age:52 years; range:23-80), with CMLBP treated at this dose as part of an ongoing Phase II study. Prior therapy for CML chronic phase included hydroxyurea alone (1 pt), alpha interferon-based therapy (7 pts), homoharringtonine (HHT) ( 1 pt), allogeneic Stem Cell Transplantation (SCT) ( 1 pt). Eleven pts had received and failed one or more prior therapy for CMLBP including topotecanbased therapy (5 pts), allogeneic SCT (3 pts), 6-thioguanine (1 pt), HHT (2 pts), mitoxantrone/ ara-C (1 pt), STI (5 pts), donor lymphocyte infusions (1 pt), 2-CDA/cyclophosphamide/ VP16U pt),hCVXD(l pt),clofarabine/decitabine(l pt),liposomalDaunorubicin/ara-C(l pt), CVAD (1 pt). Toxicities included: Grade 2 skin rash - 5 pts; hand-foot syndrome: Grade 2-4 pts, Grade 3-3 pts; Grade 2 mucositis - 1 pt; Grade 4 mucositis - 2 pts. Three patients were converted to 2nd chronic phase with a median duration of 10 months (range 9-16). Two pts had early deaths from progressive disease and two others are too early to assess. Four patients have received two or more courses of therapy. Troxatyl(tm) has activity in heavily pretreated patients with CMLBP and merits further study in first line as a single agent and in combination.

AB - Troxatyl™ is the first dioxolane nucleoside with potent in vitro and in vivo antitumor activity. This cytosine analog is a DNA polymerase inhibitor and complete DNA chain terminator. It undergoes cellular uptake with prolonged retention of the phosphorylated metabolites. Troxatyl™ is not a substrate for cytidine deaminase and is the only L-isomer nucleoside analog with anti-tumor activity. In a Phase I study of Troxatyl™ in patients (pts) with primary refractory or relapsed acute leukemia, mucositis and hand-foot syndrome were the dose limiting toxicities. (Giles el al Abstract 4231 ASH 1999). The recommended single agent dose was defined as 8 mg/m2/day daily for 5 days. Preliminary results are presented for 13 pts ( 10 female and 3 male, median age:52 years; range:23-80), with CMLBP treated at this dose as part of an ongoing Phase II study. Prior therapy for CML chronic phase included hydroxyurea alone (1 pt), alpha interferon-based therapy (7 pts), homoharringtonine (HHT) ( 1 pt), allogeneic Stem Cell Transplantation (SCT) ( 1 pt). Eleven pts had received and failed one or more prior therapy for CMLBP including topotecanbased therapy (5 pts), allogeneic SCT (3 pts), 6-thioguanine (1 pt), HHT (2 pts), mitoxantrone/ ara-C (1 pt), STI (5 pts), donor lymphocyte infusions (1 pt), 2-CDA/cyclophosphamide/ VP16U pt),hCVXD(l pt),clofarabine/decitabine(l pt),liposomalDaunorubicin/ara-C(l pt), CVAD (1 pt). Toxicities included: Grade 2 skin rash - 5 pts; hand-foot syndrome: Grade 2-4 pts, Grade 3-3 pts; Grade 2 mucositis - 1 pt; Grade 4 mucositis - 2 pts. Three patients were converted to 2nd chronic phase with a median duration of 10 months (range 9-16). Two pts had early deaths from progressive disease and two others are too early to assess. Four patients have received two or more courses of therapy. Troxatyl(tm) has activity in heavily pretreated patients with CMLBP and merits further study in first line as a single agent and in combination.

UR - http://www.scopus.com/inward/record.url?scp=33748580645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748580645&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748580645

VL - 96

SP - 254b

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART II

ER -